Harmony Biosciences (HRMY) CMO granted options and RSUs

Rhea-AI Filing Summary

Harmony Biosciences (HRMY) chief medical officer Budur Kumar reported new equity awards and routine tax withholding transactions. On January 22, 2026, Kumar received a stock option for 42,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 with the remainder vesting quarterly until the fourth anniversary, subject to continued service. On the same date, Kumar was granted 12,200 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.

On January 24 and 25, 2026, portions of earlier RSU grants vested, converting 2,188 and 2,662 RSUs into common shares. The company withheld 1,153 and 1,372 shares, respectively, at a price of $36.82 per share to satisfy income tax obligations, leaving 1,035 and 1,290 shares directly held after each event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Budur Kumar

(Last) (First) (Middle)

630 W GERMANTOWN PIKE

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/24/2026		M		2,188	A	$0	2,188	D
Common Stock(1)	01/24/2026		F		1,153	D	$36.82	1,035	D
Common Stock	01/25/2026		M		2,662	A	$0	2,662	D
Common Stock(1)	01/25/2026		F		1,372	D	$36.82	1,290	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$36.76	01/22/2026		A		42,600		(2)	01/22/2036	Common Stock	42,600	$0	42,600	D
Restricted Stock Units	(3)	01/22/2026		A		12,200		(3)	(3)	Common Stock	12,200	$0	12,200	D
Restricted Stock Units(4)	(4)	01/24/2026		M			2,188	(4)	(4)	Common Stock	2,188	$0	4,175	D
Restricted Stock Units(5)	(5)	01/25/2026		M			2,662	(5)	(5)	Common Stock	2,662	$0	7,988	D

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.

2. The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

3. The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

4. This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

5. This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

	/s/ Christian Ulrich, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Harmony Biosciences (HRMY) report for Budur Kumar?

The filing shows that chief medical officer Budur Kumar received new stock options and RSUs on January 22, 2026, and that portions of prior RSU grants vested on January 24 and 25, 2026, with shares withheld to cover taxes.

How many stock options were granted to the Harmony Biosciences CMO in this Form 4?

Kumar was granted a stock option for 42,600 shares of Harmony Biosciences common stock at an exercise price of $36.76 per share, vesting over four years starting January 22, 2027, subject to continued service.

What restricted stock unit (RSU) awards does the Form 4 disclose for HRMY?

The filing reports a new grant of 12,200 RSUs on January 22, 2026, vesting in four equal annual installments beginning January 22, 2027. It also reflects vesting of previously granted RSUs from January 24, 2024 and January 25, 2025 awards.

Were any Harmony Biosciences shares sold in the market in this insider filing?

The Form 4 shows transactions coded "F", indicating shares were withheld by the issuer at $36.82 per share to satisfy income tax withholdings upon RSU vesting, rather than open-market sales initiated by the insider.

How many Harmony Biosciences shares did the CMO hold after the reported RSU vesting events?

Following the January 24, 2026 RSU vesting and related tax withholding, Kumar directly held 1,035 shares of common stock from that line. After the January 25, 2026 RSU vesting and withholding, the reported directly held amount on that line was 1,290 shares.

What are the vesting terms for the stock options and RSUs granted to the HRMY CMO?

The stock option vests 25% on January 22, 2027, with the remaining 75% vesting quarterly until the fourth anniversary of the grant date. The 12,200 RSUs vest in four equal annual installments beginning January 22, 2027, each contingent on Kumar’s continued service through the applicable vesting date.